Are the new SARS-CoV-2 variants resistant against the vaccine?
作者信息
Abdalla Mohnad, El-Arabey Amr Ahmed, Jiang Xinyi
机构信息
Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, PR China.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
出版信息
Hum Vaccin Immunother. 2021 Oct 3;17(10):3489-3490. doi: 10.1080/21645515.2021.1925503. Epub 2021 May 28.
Abstract
摘要
相似文献
1
Are the new SARS-CoV-2 variants resistant against the vaccine?
Hum Vaccin Immunother. 2021 Oct 3;17(10):3489-3490. doi: 10.1080/21645515.2021.1925503. Epub 2021 May 28.
2
Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Viruses. 2021 Jul 22;13(8):1421. doi: 10.3390/v13081421.
3
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Microbiol Spectr. 2021 Dec 22;9(3):e0096521. doi: 10.1128/Spectrum.00965-21. Epub 2021 Nov 10.
4
Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.
Protein Cell. 2021 Oct;12(10):818-823. doi: 10.1007/s13238-021-00840-z. Epub 2021 Apr 28.
5
Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
mBio. 2021 Dec 21;12(6):e0265621. doi: 10.1128/mBio.02656-21. Epub 2021 Dec 7.
6
Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies.
Zool Res. 2021 Nov 18;42(6):789-791. doi: 10.24272/j.issn.2095-8137.2021.343.
7
Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Front Immunol. 2021 Dec 23;12:786554. doi: 10.3389/fimmu.2021.786554. eCollection 2021.
8
Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8 T cell responses.
Cell Rep Med. 2022 Jan 19;3(2):100520. doi: 10.1016/j.xcrm.2022.100520. eCollection 2022 Feb 15.
9
Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
EBioMedicine. 2021 Nov;73:103677. doi: 10.1016/j.ebiom.2021.103677. Epub 2021 Nov 3.
10
A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
Emerg Microbes Infect. 2021 Dec;10(1):1555-1573. doi: 10.1080/22221751.2021.1957400.
引用本文的文献
1
Kinetics of severe acute respiratory syndrome coronavirus 2 infection antibody responses.
Front Immunol. 2022 Aug 5;13:864278. doi: 10.3389/fimmu.2022.864278. eCollection 2022.
2
Identification of a novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small-molecule derivative of quinolone.
Comput Biol Med. 2022 Sep;148:105814. doi: 10.1016/j.compbiomed.2022.105814. Epub 2022 Jul 11.
3
Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2.
Immunotargets Ther. 2022 May 18;11:23-35. doi: 10.2147/ITT.S360151. eCollection 2022.
4
Secondary Infections in Patients with COVID-19 Pneumonia Treated with Tocilizumab Compared to Those Not Treated with Tocilizumab: A Retrospective Study at a Tertiary Hospital in Kenya.
Int J Gen Med. 2022 Mar 3;15:2415-2425. doi: 10.2147/IJGM.S356547. eCollection 2022.
5
Molecular dynamic study of SARS-CoV-2 with various S protein mutations and their effect on thermodynamic properties.
Comput Biol Med. 2022 Feb;141:105025. doi: 10.1016/j.compbiomed.2021.105025. Epub 2021 Nov 9.
6
Vaccines efficacy to SARS-CoV-2 variants require holistic knowledge of viral immunology and protein biochemistry.
Hum Vaccin Immunother. 2021 Nov 2;17(11):4128-4130. doi: 10.1080/21645515.2021.1964318. Epub 2021 Sep 8.
Zotero 插件